Literature DB >> 15951321

Six novel mutations in the proopiomelanocortin and melanocortin receptor 4 genes in severely obese adults living in southern Italy.

Pasqualina Buono1, Fabrizio Pasanisi, Carmela Nardelli, Luigi Ieno, Silvana Capone, Rosario Liguori, Carmine Finelli, Giovannangelo Oriani, Franco Contaldo, Lucia Sacchetti.   

Abstract

BACKGROUND: The genetic characterization of obese individuals could clarify the molecular mechanisms underlying body weight regulation and lead to targeted therapy. Here we report variants of the proopiomelanocortin (POMC) and melanocortin receptor 4 (MC4R) genes detected in severely obese adults living in southern Italy.
METHODS: A total of 196 unrelated nondiabetic severely obese individuals [111 females and 85 males; mean (SD) age, 32.2 (11.5) years; mean body mass index, 48.8 (8.1) kg/m(2)] and 100 normal-weight healthy volunteers (34 males and 66 females) entered the study. POMC and MC4R were genotyped by sequencing analysis. Leptin, insulin, glucose, and the lipid profile were measured in fasting serum samples. We used the protein truncation test to verify the stop-codon mutation. Anthropometric measurements, sitting blood pressure, and heart rate were also recorded.
RESULTS: Of the obese participants, 1.5% had mutations in POMC exon 3 (new mutations, P231L and E244X; known, R236G) and 2.5% had MC4R mutations (new mutations, W174C, Q43X, S19fsX51, and I317V; known, A175T). These mutations were not present in the controls. Gene polymorphisms were identified in similar percentages of severely obese and nonobese individuals, i.e., respectively, 52.5% and 51% (POMC) and 1% and 2% (MC4R).
CONCLUSIONS: We detected 2 new POMC mutations and 4 new MC4R mutations in a large number of severely obese adults living in southern Italy. These mutations, not present in normal-weight individuals, are further evidence that defects in the melanocortin pathway are related to severe obesity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15951321     DOI: 10.1373/clinchem.2005.047886

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  13 in total

1.  Identification and functional characterization of novel mutations in the melanocortin-4 receptor.

Authors:  Sigri Beckers; Doreen Zegers; Fenna de Freitas; Armand V Peeters; Stijn L Verhulst; Guy Massa; Luc F Van Gaal; Jean-Pierre Timmermans; Kristine N Desager; Wim Van Hul
Journal:  Obes Facts       Date:  2010-10-15       Impact factor: 3.942

Review 2.  POMC: The Physiological Power of Hormone Processing.

Authors:  Erika Harno; Thanuja Gali Ramamoorthy; Anthony P Coll; Anne White
Journal:  Physiol Rev       Date:  2018-10-01       Impact factor: 37.312

3.  Pharmacological characterization of 30 human melanocortin-4 receptor polymorphisms with the endogenous proopiomelanocortin-derived agonists, synthetic agonists, and the endogenous agouti-related protein antagonist.

Authors:  Zhimin Xiang; Bettina Proneth; Marvin L Dirain; Sally A Litherland; Carrie Haskell-Luevano
Journal:  Biochemistry       Date:  2010-06-08       Impact factor: 3.162

4.  The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology.

Authors:  Ya-Xiong Tao
Journal:  Endocr Rev       Date:  2010-02-26       Impact factor: 19.871

5.  An overview of mongenic and syndromic obesities in humans.

Authors:  Wendy K Chung
Journal:  Pediatr Blood Cancer       Date:  2011-10-12       Impact factor: 3.167

6.  A Common variant near the melanocortin 4 receptor is associated with low-density lipoprotein cholesterol and total cholesterol in the Chinese Han population.

Authors:  Liming Tao; Zhou Zhang; Zhuo Chen; Daizhan Zhou; Weidong Li; Mengyuan Kan; Di Zhang; Lin He; Guoying Huang; Yun Liu
Journal:  Mol Biol Rep       Date:  2012-02-17       Impact factor: 2.316

7.  Single Nucleotide Polymorphisms in the Melanocortin His-Phe-Arg-Trp Sequences Decrease Tetrapeptide Potency and Efficacy.

Authors:  Marshall D Winget; Mark D Ericson; Katie T Freeman; Carrie Haskell-Luevano
Journal:  ACS Med Chem Lett       Date:  2019-07-02       Impact factor: 4.345

8.  Lower metabolic rate in individuals heterozygous for either a frameshift or a functional missense MC4R variant.

Authors:  Jonathan Krakoff; Lijun Ma; Sayuko Kobes; William C Knowler; Robert L Hanson; Clifton Bogardus; Leslie J Baier
Journal:  Diabetes       Date:  2008-10-03       Impact factor: 9.461

9.  Prevalence of pathogenetic MC4R mutations in Italian children with early onset obesity, tall stature and familial history of obesity.

Authors:  Nicola Santoro; Grazia Cirillo; Zhimin Xiang; Rita Tanas; Nella Greggio; Giuseppe Morino; Lorenzo Iughetti; Alessandra Vottero; Alessandro Salvatoni; Mario Di Pietro; Antonio Balsamo; Antonino Crinò; Anna Grandone; Carrie Haskell-Luevano; Laura Perrone; Emanuele Miraglia del Giudice
Journal:  BMC Med Genet       Date:  2009-03-12       Impact factor: 2.103

10.  Functional characterization and pharmacological rescue of melanocortin-4 receptor mutations identified from obese patients.

Authors:  Zhen-Chuan Fan; Ya-Xiong Tao
Journal:  J Cell Mol Med       Date:  2009-02-27       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.